Proto-oncogene tyrosine-protein kinase receptor Ret — Drug Target

All drugs that target Proto-oncogene tyrosine-protein kinase receptor Ret — marketed and clinical-stage. Includes 2 drug classes acting on this target.

Drug classes

Kinase Inhibitor [EPC] · Proton Pump Inhibitors

Marketed (2)

• Lenvima · Eisai · Kinase Inhibitor [EPC] · Oncology
  Lenvima works by blocking the activity of a specific protein called Ret, which is involved in the growth and spread of cancer cells.
• Retevmo · Eli Lilly · Kinase Inhibitor [EPC] · Oncology
  Retevmo works by blocking the activity of the RET protein, which is involved in the growth and spread of cancer cells.

Phase 3 pipeline (1)

• Amitriptyline Oxide · Oncology
  Amitriptylinoxide works by binding to and inhibiting the proto-oncogene tyrosine-protein kinase receptor Ret.